English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT02773030 /

CC-220-MM-001

A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: